Why the study?
Does enalapril and verapamil SR improve pharmacoeconomical and clinical parameters compared to enalapril and amlodipine in hypertensive patients with metabolic syndrome?
RCT (n=150)
Randomized in 2 matching groups
Does enalapril and verapamil SR improve pharmacoeconomical and clinical parameters compared to enalapril and amlodipine in hypertensive patients with metabolic syndrome?
Enalapril combined with verapamil SR provides pharmacoeconomical benefits and improved pulse pressure and diastolic function compared to enalapril with amlodipine in hypertensive patients with metabolic syndrome.
Supports enalapril-verapamil SR over amlodipine add-on in metabolic syndrome hypertension; extends dual-therapy optimization evidence.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Сидоренкова et al. (2009) conducted an RCT in Arterial hypertension and metabolic syndrome (n=150). Enalapril and verapamil SR vs. Enalapril and amlodipine was evaluated on 24-hour blood pressure, echocardiography parameters, microalbuminuria, metabolic profile, and cost/efficiency.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: